Oligoclonal IgG bands (OCB) in cerebrospinal fluid (CSF) are important in diagnosis of multiple sclerosis (MS). We evaluated the MRI features of clinically definite MS subjects with and without CSF-OCB. Relapsing MS subjects were recruited from a prospective registry in a university center. CSF-OCB were detected using isoelectric focusing and lgG-specific immunofixation. MRI metrics including brain volumes, lesion volumes and microstructural measures, were analyzed by fMRiB Software Library (fSL) and Statistical parametric Mapping (SpM). Seventy-five subjects with relapsing MS were analyzed. Forty-four (59%) subjects had an interval MRI at around 1 year. CSF-OCB were detected in 46 (61%) subjects. The OCB-positive group had a higher proportion of cerebellar lesions than the OCB-negative group (23.9% vs. 3.4%, p = 0.057). Except for amygdala volumes which were lower in the OCB-positive group (p = 0.034), other regional brain volumes including the subcortical deep gray matter and corpus callosum were similar. the two groups also showed comparable brain atrophy rate. For DTI, the OCB-positive group showed significantly higher mean diffusivity (MD) value in perilesional normal-appearing white matter (p = 0.043). Relapsing MS patients with and without CSF-OCB shared similar MRi features regarding volumetric analyses and Dti microstructural integrity. Oligoclonal IgG bands (OCB) in the cerebrospinal fluid (CSF) are one of the most sensitive biomarkers in the diagnostic work-up of multiple sclerosis (MS), and inclusion of their presence into the updated McDonald criteria has improved clinical diagnosis 1. Up to 95% of Caucasian patients and 60% of Asian patients with MS are positive for CSF-OCB 2,3. Limited data support that CSF-OCB may be involved in the pathogenesis of MS; some pathological studies revealed that tissue damage may be underpinned by other types of oligoclonal bands such as IgM 4. Meanwhile, the relationship between CSF-OCB status and disease characteristics, such as clinical course, disease progression, responses to disease modifying therapies, remain unclear 3,5. Magnetic resonance imaging (MRI) is now standard of care in the management of MS, allowing diagnosis and monitoring of treatment response in clinical practice 6. Compared to conventional MRI alone, the use of high-resolution images, advanced pulse sequences and advanced computational techniques provides a more comprehensive information on the pathophysiological extent of disease. For instance, volumetric imaging allows a more precise quantitative assessment of brain atrophy which in turn has been shown to occur early in the disease course and is associated with disease progression of MS 7,8. Recent clinical trials have incorporated brain atrophy, at an annual brain volume loss (BVL) rate threshold of 0.4%, as a secondary outcome measure and marker of neurodegeneration in MS 9. Meanwhile, diffusion tensor imaging (DTI) allows microstructural assessment of white matter integrity by quantifying the magnitude and directionality of the molecular di...